Cellectis (NASDAQ:CLLS) Upgraded to “Buy” at StockNews.com

Cellectis (NASDAQ:CLLS) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Cellectis Trading Up 6.5 %

Shares of Cellectis stock opened at $1.32 on Monday. The company has a fifty day simple moving average of $1.41 and a 200-day simple moving average of $1.72. Cellectis has a 12-month low of $1.14 and a 12-month high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $73.37 million, a price-to-earnings ratio of -1.02 and a beta of 3.27.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million. On average, equities analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares during the period. B Group Inc. acquired a new position in shares of Cellectis in the 4th quarter valued at $5,547,000. Finally, Millennium Management LLC purchased a new stake in Cellectis in the 4th quarter valued at $962,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.